Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

RGLS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.41%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $23,857.12

Regulus Therapeutics Insider Trading History Chart

Regulus Therapeutics Share Price & Price History

^$2.20

▲ +0.07 (3.29%)

As of 04/22/2024 01:00 AM ET

Days: 30 | 90 | 365

[Shocking] Elon Musk’s Plan To End Banks

From Crypto 101 Media | Ad

Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.

Click here now to get your copy.

Regulus Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/18/2024	Crispina Calsada	CFO	Sell	5,468	$1.19	$6,506.92	5,782
1/18/2024	Joseph P. Hagan	CEO	Sell	14,580	$1.19	$17,350.20	57,112
2/4/2022	Denis Drygin	Insider	Buy	23,314	$0.23	$5,362.22
1/26/2022	Joseph P. Hagan	CEO	Buy	100,000	$0.22	$22,000.00
5/17/2021	Christopher Ray Aker	VP	Sell	860	$0.89	$765.40	41,754
5/17/2021	Joseph P. Hagan	CEO	Sell	4,186	$0.89	$3,725.54	316,292

[Shocking] Elon Musk’s Plan To End Banks

From Crypto 101 Media | Ad

Click here now to get your copy.

SEC Filings (Institutional Ownership Changes) for Regulus Therapeutics (NASDAQ:RGLS)

92.38% of Regulus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Regulus Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/22/2024	Vivo Capital LLC	5,000,000	$14.40M	1.1%	N/A	7.638%
2/5/2024	Victory Capital Management Inc.	271,736	$0.35M	0.0%	+16.5%	1.344%
11/13/2023	FMR LLC	2,922,600	$4.03M	0.0%	+32.4%	14.454%
11/6/2023	Victory Capital Management Inc.	233,207	$0.32M	0.0%	+5.3%	1.197%
8/14/2023	Prelude Capital Management LLC	40,660	$60K	0.0%	N/A	0.209%
9/16/2022	Federated Hermes Inc.	2,904,826	$6.01M	0.0%	-90.0%	19.850%
8/16/2022	DAFNA Capital Management LLC	555,555	$1.15M	0.3%	-90.0%	3.797%
8/12/2022	Ikarian Capital LLC	105,341	$0.22M	0.0%	-91.8%	0.722%
8/1/2022	Victory Capital Management Inc.	221,506	$0.46M	0.0%	-90.1%	1.517%
7/19/2022	Commonwealth Equity Services LLC	22,000	$45K	0.0%	-83.2%	0.151%
2/14/2022	DAFNA Capital Management LLC	5,555,555	$1.75M	0.4%	N/A	6.382%
1/19/2022	Asymmetry Capital Management L.P.	2,731,044	$0.86M	0.5%	+94.9%	3.137%
11/15/2021	GSA Capital Partners LLP	64,708	$45K	0.0%	-68.6%	0.074%
11/4/2021	Asymmetry Capital Management L.P.	1,401,491	$0.97M	0.6%	-3.4%	1.610%
10/29/2021	Commonwealth Equity Services LLC	111,000	$76K	0.0%	+38.8%	0.128%
9/17/2021	Virtu Financial LLC	79,193	$64K	0.0%	N/A	0.091%
8/27/2021	Endurant Capital Management LP	2,607,674	$2.12M	0.6%	+9.7%	2.996%
8/16/2021	State Street Corp	176,494	$0.14M	0.0%	N/A	0.203%
8/13/2021	Geode Capital Management LLC	589,196	$0.48M	0.0%	+54.3%	0.786%
8/13/2021	Vanguard Group Inc.	3,095,237	$2.52M	0.0%	-3.9%	4.131%
8/12/2021	Lido Advisors LLC	57,500	$47K	0.0%	N/A	0.077%
8/11/2021	Commonwealth Equity Services LLC	80,000	$65K	0.0%	+300.0%	0.107%
8/10/2021	Strategic Wealth Advisors Group LLC	74,800	$61K	0.0%	N/A	0.100%
8/5/2021	GSA Capital Partners LLP	206,265	$0.17M	0.0%	N/A	0.275%
7/31/2021	Asymmetry Capital Management L.P.	1,450,777	$1.18M	0.8%	-26.9%	1.936%
7/15/2021	Focused Wealth Management Inc	200,000	$0.16M	0.0%	+100.0%	0.267%
5/19/2021	Squarepoint Ops LLC	159,804	$0.25M	0.0%	+1,477.7%	0.213%
5/17/2021	Endurant Capital Management LP	2,376,557	$3.71M	1.0%	N/A	3.172%
5/17/2021	Ikarian Capital LLC	1,245,989	$1.94M	0.1%	N/A	1.663%
5/17/2021	Atom Investors LP	337,228	$0.53M	0.1%	N/A	0.450%
5/17/2021	Goldman Sachs Group Inc.	18,049	$28K	0.0%	-68.0%	0.024%
5/12/2021	Northern Trust Corp	117,654	$0.18M	0.0%	+198.4%	0.157%
5/12/2021	Geode Capital Management LLC	381,892	$0.60M	0.0%	+493.5%	0.510%
5/11/2021	Acadian Asset Management LLC	465,678	$0.73M	0.0%	N/A	0.622%
5/11/2021	Asymmetry Capital Management L.P.	1,985,472	$3.10M	1.6%	N/A	2.650%
5/4/2021	Commonwealth Equity Services LLC	20,000	$31K	0.0%	N/A	0.027%
5/4/2021	Victory Capital Management Inc.	2,227,199	$3.47M	0.0%	+345.4%	2.976%
5/3/2021	Focused Wealth Management Inc	100,000	$0.16M	0.0%	N/A	0.134%
2/10/2021	Renaissance Technologies LLC	449,200	$0.61M	0.0%	N/A	1.147%
2/5/2021	BlackRock Inc.	49,788	$68K	0.0%	-23.2%	0.127%
2/2/2021	Grimes & Company Inc.	54,511	$74K	0.0%	+127.1%	0.139%
2/2/2021	GYL Financial Synergies LLC	51,376	$69K	0.0%	N/A	0.131%
2/1/2021	Victory Capital Management Inc.	499,989	$0.68M	0.0%	N/A	1.277%
10/20/2020	Wedbush Securities Inc.	70,204	$36K	0.0%	+241.2%	0.193%
8/14/2020	BVF Inc. IL	1,450,000	$0.99M	0.1%	-9.0%	6.892%
8/7/2020	Virtu Financial LLC	84,348	$57K	0.0%	N/A	0.401%
5/12/2020	Rockefeller Capital Management L.P.	84,642	$39K	0.0%	-22.9%	0.402%

Data available starting January 2016

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $2.20

$2.09

$2.26

50 Day Range

MA: $2.14

$1.38

$2.88

52 Week Range

Now: $2.20

$1.08

$3.79

Volume

127,028 shs

Average Volume

2,513,714 shs

Market Capitalization

$144.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Who are the company insiders with the largest holdings of Regulus Therapeutics?: Regulus Therapeutics' top insider investors include:
Joseph P Hagan (CEO)
Crispina Calsada (CFO)
Learn More about top insider investors at Regulus Therapeutics.
Who are the major institutional investors of Regulus Therapeutics?: Regulus Therapeutics' top institutional investors include:
Vivo Capital LLC — 7.64%
Learn More about top institutional investors of Regulus Therapeutics stock.
Which institutional investors are buying Regulus Therapeutics stock?: Within the last quarter, RGLS stock was bought by institutional investors including:
Vivo Capital LLC